Journal: Bioscience Reports
Article Title: The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis
doi: 10.1042/BSR20253205
Figure Lengend Snippet: (i) Control group; (ii) DDS group, dextran sodium sulphate (DSS) at 2% w/v was administered to induce colitis; (iii) AZD group, myeloperoxidase (MPO) inhibitor AZD3241 at 30 mg/kg was provided to mice daily in peanut butter (PB) through the experiment; (iv) GSK group, peptidyl-arginine deiminase IV (PAD4) inhibitor GSK484 at 4 m/kg was injected via i.p. every second day. (v) AZD+GSK inhibitors group, both treatments were administered following the conditions mentioned above.
Article Snippet: Ratio difference calculation between the two MPO inhibitors showed that AZD3241 from MedChemExpress contained ~42% of the compound of interest relative to the same weight of inhibitor supplied by Pharmaxis.
Techniques: Control, Injection